AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02548533 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: AFXL
Description: Pretreatment at 2.5 mJ/microbeam and 15% density.
Study NCT02548533 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AHES
Description: Topical application on AFXL pretreated skin 15 minutes prior to the treatment.
Study NCT02548533 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: EMLA cream
Description: Topical application 2 hours prior to the treatment.
Study NCT01645852 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Optifast 800
Description: Five units of Optifast 800 plus an unlimited volume of calorie-free fluids per day for one week prior to hepatic resection.
Study NCT02000505 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PocketCPR
Description: 5 minutes chest-compression-only CPR, using Zoll PocketCPR
Study NCT02000505 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Metronome
Description: 5 minutes chest-compression-only CPR, using a metronome
Study NCT02000505 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 110bpm Song
Description: 5 minutes chest-compression-only CPR, using a song with 110bpm for support
Study NCT03022903 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Aminolevulinic Acid (ALA)
Description: Photosensitizing
Study NCT04545606 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: In-Person CBT for insomnia in children with autism
Description: 7 modules administered in-person~1. Sleep Hygiene \& Sleep Prescription~2. Bedtime Routine \& Parent Management~3. Cue Control \& Parent Management~4. Co-Sleeping \& Parents Fading out of Room~5. Circadian Education, Morning Routine, \& Relaxation~6. Cognitive Therapy Basics~7. Nighttime Fears, Anxiety, \& Nightmares
Study NCT04545606 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Remote CBT for insomnia in children with autism
Description: 7 modules administered over telehealth/videoconferencing~1. Sleep Hygiene \& Sleep Prescription~2. Bedtime Routine \& Parent Management~3. Cue Control \& Parent Management~4. Co-Sleeping \& Parents Fading out of Room~5. Circadian Education, Morning Routine, \& Relaxation~6. Cognitive Therapy Basics~7. Nighttime Fears, Anxiety, \& Nightmares
Study NCT04545606 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Remote sleep hygiene and related education (SHARE) for insomnia in children with autism
Description: 7 modules administered over telehealth/videoconferencing~1. Sleep Education~2. Sleep Architecture \& Parasomnias~3. Physical Activity \& Sleep~4. Nutrition, My Plate, \& Breathing during Sleep~5. Stress, Sleep, Dreams, \& Nightmares Connections~6. Mood, Self-Esteem, \& Sleep~7. Light \& Dark Cycle
Study NCT00631917 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aliskiren
Description: Aliskiren 300 mg once a day
Study NCT00631917 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ramipril
Description: Ramipril 10 mg once a day
Study NCT00631917 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo to Ramipril
Description: Placebo capsules to match ramipril.
Study NCT06638983 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Non-extraction Orthodontic Treatment of Angle Class I Malocclusion
Description: Cephalometric radiographs, and extraoral and intraoral photographs, and cast impressions were collected before and after intervention. The weighted PAR Index (Peer Assessment Rating) employed to determine outcome of orthodontic treatment. Also the following soft tissue and bone indexes were assessed before and after intervention
Study NCT02277730 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: vasopressor delivery automated system
Description: vasopressor delivery using phenylephrine and ephedrine
Study NCT06643221 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise
Description: After an initial maximal graded exercise test to determine maximal oxygen uptake and peak cycling power, healthy participants will undergo a 20-minute graded exercise test at intensities corresponding to 50, 60, 70 and 80% VO2max (5-minutes per stage)
Study NCT06643221 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Isoproterenol
Description: To determine if pharmacological activation of beta-adrenergic receptors evokes an immune respponse akin to exercise, healthy participants will receive an intravenous infusion of isoproterenol (50ng/kg/min)
Study NCT06643221 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Healthy participants will consume the placebo 2-3h prior to completing a 20-minute graded exercise test at intensities ranging from 50-80-% of the maximal oxygen uptake
Study NCT06643221 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Bisoprolol Fumarate Tablet 10 mg
Description: Healthy participants will consume a 10mg Bisoprolol Fumerate tablet 2-3h prior to completing a 20-minute graded exercise test at intensities ranging from 50-80-% of the maximal oxygen uptake
Study NCT06643221 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Nadolol (1 x 80 mg) Tablets (Invamed, Inc)
Description: Healthy participants will consume a 80mg Nadolol tablet 2-3h prior to completing a 20-minute graded exercise test at intensities ranging from 50-80-% of the maximal oxygen uptake
Study NCT06643221 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Carvedilol 50 mg
Description: Healthy participants will consume a 50mg Carvedilol tablet 2-3h prior to completing a 20-minute graded exercise test at intensities ranging from 50-80-% of the maximal oxygen uptake
Study NCT06643221 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Roflumilast 500 Mcg Oral Tablet
Description: Healthy participants will consume a 500mcg Roflumilast tablet and a 10mg Bisoprolol tablet 2-3h prior to completing a 20-minute graded exercise test at intensities ranging from 50-80-% of the maximal oxygen uptake
Study NCT02495532 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Lymph node clearing technique with GEWF solution
Description: Procedure: lymph node clearing technique with GEWF solution~(1) just after the surgical resection each specimen is fixed by formaldehyde; (2) lymph node harvesting is performed by a manual technique of vision and palpation; (3) lymph nodes retrieved are counted, stained with hematoxylin and eosin and examined with light microscopy; (4) the surgical specimen is submitted to re-fixation with GEWF solution and another lymph node harvesting by manual technique of vision and palpation; (5) additional lymph nodes retrieved are counted, stained with hematoxylin and eosin and examined with light microscopy.
Study NCT04157452 — intervention group
Intervention type: PROCEDURE
Intervention: flexible ureteroscopy
Description: flexible ureteroscopy is used to removed the stone. If a double-J stent was inserted pre-operatively, it was removed at the beginning of surgery. Rigid ureteroscopy was routinely used for ureteral dilatation before fURS. A 0.035 mm guidewire was advanced through the urethral and ureteral meatuses to the renal pelvis under direct rigid ureteroscope vision. A 14-Fr ureteral access sheath (Cook Medical, Bloomington, IN) was then passed over the wire to the ureteropelvic junction, and 7.5-Fr fURS (Flex-X2, Karl Storz, Germany) was performed through the sheath. Intrarenal pressure was stabilized by a pressure-sensitive pump (Shenda Medical, China). Holmium: yttrium-aluminum-garnet laser was used to fragment the stones. After lithotripsy, 6-Fr double-J stent was routinely inserted in all cases for 2-4 weeks.
Study NCT01099306 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Pharmaceutical care services
Description: Patients' metabolic components were assessed and managed collaboratively by focused care plan designed by the clinical pharmacist and approved by the physician.Pharmacist emphasized the change in lifestyle, particularly weight loss and physical activity as a first line therapy for at least 3 months, patients were started on drug therapy when needed as recommended by clinical guidelines.
Study NCT03769831 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR2285
Description: Ascending dose oral adminstration
Study NCT03769831 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Ascending dose oral adminstration
Study NCT02939261 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intervention - 4 Home Visits
Description: 4 home visits from a health educator, weekly e-mails, and monthly mailed behavioural supports.
Study NCT02939261 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Control
Description: monthly emails with general health information
Study NCT04029454 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: birth dose vaccination against hepatitis B strategy
Description: Complex intervention targeting healthcare workers and involving:~* training on hepatitis B awareness and management~* training on EPI vaccination and cold chain~* training on the modalities for the birth dose administration~* the use of a monovalent unidose vaccine against Hepatitis B
Study NCT03288857 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: NeilMed Naspira
Description: NeilMed Naspira is a nasal-oral aspirator
Study NCT04258631 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydromorphone
Description: Given IT
Study NCT04258631 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Laparotomy
Description: Undergo laparotomy
Study NCT04258631 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Laparotomy
Description: Undergo laparotomy
Study NCT02277730 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: phenylephrine
Study NCT02277730 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: phenylephrine
Study NCT02277730 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ephedrine
Study NCT02083172 — intervention group
Intervention type: DEVICE
Intervention: Ultrasound Cardiac Output Monitor and 2 D-Echo
Description: Hemodynamic measurements obtained by 2D-Echo and USCOM will be compared.
Study NCT03756337 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Neuro 1 & Neuro 2
Description: participant common fitting map used for tests
Study NCT03756337 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Neuro 2 & Neuro 1
Description: participant common fitting map used for tests
Study NCT03754387 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ceftazidime
Description: Patients choosing AT group were admitted to the hospital for observation and to receive intravenous antibiotics Intravenous Ceftazidime sodium (50mg/kg/dose every 12 hours) was administered for 3 days.
Study NCT03754387 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: appendectomy
Description: APPT group consisted of admission to the hospital with promptinitiation of intravenous antibiotics and appendectomy
Study NCT01787110 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxygen
Description: see arm description
Study NCT02063217 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sodium Oxybate
Description: Sodium oxybate h.s.
Study NCT02063217 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Sleep deprivation
Description: 36hr sleep deprivation
Study NCT00638833 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Memantine
Description: Memantine 30 mg/day (20-10-0)
Study NCT00638833 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo pills
Study NCT02620059 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Lifestyle Intervention
Description: The investigators will provide information on healthy eating and physical activity. They will give pedometers to the participants to monitor their daily steps in order to increase it till 10000 steps/day.
Study NCT00891072 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: R-(-)-gossypol acetic acid
Description: Given orally
Study NCT02277730 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ephedrine
Study NCT00891072 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: paclitaxel
Description: Given IV
Study NCT00891072 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: carboplatin
Description: Given IV
Study NCT00891072 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pharmacological study
Description: Correlative studies
Study NCT03230734 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Radium-223
Description: Radium-223: administered at the dose of 55 kBq per kg body weight, given at 4 week intervals for 6 injections, by slow intravenous injection
Study NCT03230734 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: Docetaxel: administered at the dose of 75 mg/m2 by intravenous infusion over a period of 1 hour every 3 weeks for 10 cycles. It is associated with prednisone 5 mg orally twice daily administered continuously.
Study NCT02041858 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Altered Alarm Settings
Description: An altered set of alarm parameter settings
Study NCT02277730 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: manual vasopressor delivery
Study NCT03605407 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Patient visit prior to hospital admission
Description: Patient and family receiving one visit prior to hospital admission for surgery
Study NCT01453725 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Golimumab
Description: Golimumab 50 mg SC injection every 4 weeks
Study NCT01453725 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Golimumab
Description: Golimumab 50 mg SC injection every 4 weeks
Study NCT01453725 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo SC injection every 4 weeks
Study NCT00871325 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daikenchuto (TU-100)
Description: Subjects will receive 2.5g TID (7.5g/day) of TU-100. Dosage form is a granule. Subject will take a daily dose divided three times a day for 5 days.
Study NCT00871325 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daikenchuto (TU-100)
Description: Subjects will receive 5g TID (15g/day) of TU-100. Dosage form is a granule. Subject will take a daily dose divided three times a day for 5 days.
Study NCT00871325 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Subjects will receive daily dose of TU-100 placebo. Dosage form is a granule. Subject will take a daily dose divided three times a day for 5 days.
Study NCT02309593 — intervention group
Intervention type: DEVICE
Intervention: PROFEMUR® Xm Femoral Stems
Description: THA using PROFEMUR® Xm Femoral Stems
Study NCT01724931 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LD-aminopterin
Study NCT01724931 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Study NCT04226339 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: total knee arthroplasty with a kinetic alignment
Description: During surgery, a SPHERE prosthesis will replace the knee and the femorotibial alignment.~it will be set to reproduce the preoperative constitutional deformity in varus or valgus as it was measured before surgery
Study NCT04226339 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: total knee arthroplasty with a mechanical alignment
Description: During surgery, a SPHERE prosthesis will replace the knee and the femorotibial alignment.~It will be set to 180° as defined for a mechanical femorotibial alignment
Study NCT01605071 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Estradiol
Description: 1 week of transdermal estradiol (0.15mg)~1 week of transdermal placebo
Study NCT04258631 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Liposomal Bupivacaine
Description: Drug
Study NCT04258631 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Liposomal Bupivacaine
Description: Drug
Study NCT02424955 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: perflutren lipid microspheres
Study NCT02424955 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: 3D ultrasound
Study NCT04258631 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Questionnaire Administration
Description: Ancillary studies
Study NCT04258631 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies
Study NCT03331354 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Distant vocational learning
Description: use of hybrid distance learning to facilitate successful employment outcomes
Study NCT03331354 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Basic vocational services
Description: self-help manual
Study NCT04025957 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR-1501
Description: Administered subcutaneously
Study NCT02898610 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Colchicine
Study NCT04051021 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Comfort Coach
Description: A trained comfort coach will provide emotional and psychological interventions at six time points: preoperative clinic, day of surgery, extubation, chest tube removal, discharge, 30-day clinic follow-up, and 90-day post-discharge. Patients will also complete surveys at specific time points (preoperative clinic, hospital discharge, 30-day clinic follow-up, and 90-day post-discharge).
Study NCT03044054 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ECHOPULSE
Description: HIFU Under ultrasound guidance
Study NCT04639726 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Whey Protein Micro Gel
Description: The test product is whey protein microgels 10g, reconstituted in 125ml water.
Study NCT04639726 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Water without Whey Protein.
Description: A matching placebo (125ml of water without whey protein) will be used as control.
Study NCT01923038 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: First arm: patients ventilated with zero end expiratory pressure
Study NCT01923038 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Patients ventilated with Positive End Expiratory Pressure
Study NCT01923038 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Patients ventilated with Positive End Expiratory Pressure plus Recruitment maneuver
Study NCT01600651 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Recruitment Maneuver (RM) sham group
Description: It 's when RM sequence precedes a shame evaluation period
Study NCT01600651 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham recruitment maneuver (RM) group
Description: Group in which patients receive a sham sequence before the RM sequence
Study NCT03132987 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Progressive strengthening program
Description: The progressive strengthening program will be performed for 3 weeks and emphasize development of strength and power. Feasibility will be established if we can recruit up to 8 participants and retain at least 80% over the 3 week intervention program. We will determine effect sizes for changes outcome measures.
Study NCT01181908 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: single dose
Description: Subjects will receive a single dose of GSK1144814 or placebo.
Study NCT01181908 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: single dose
Description: Subjects will receive a single dose of GSK1144814 or placebo.
Study NCT04051021 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Usual Care
Description: Patients will complete surveys at specific time points (preoperative clinic, hospital discharge, 30-day clinic follow-up, and 90-day post-discharge).
Study NCT03613415 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Expansion
Description: non invasive technique to increase thickness of thin ridge
Study NCT03613415 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Expansion
Description: non invasive technique to increase thickness of thin ridge
Study NCT00206999 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: imipramine
Description: Either 50 mg of imipramine or placebo will be administered to healthy male volunteers
Study NCT04080154 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anlotinib
Description: 12mg orally (p.o.) every day (qd) for 2 weeks of every 3 week cycle (i.e. 2 weeks on, 1 week off)
Study NCT01543464 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chemotherapy: Temozolomide
Description: Vaccine: 250 microgram IDO5 peptide + 250 microgram Survivin peptide + 500 microL Montanide every 2nd week Adjuvants: 75 microgram GM-CSF + 1 application Imiquimod every 2nd week
Study NCT03649958 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: HIRREM-SOP or Cereset
Description: HIRREM-SOP for ten 90 minute sessions
Study NCT03649958 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Cereset 2x
Description: Cereset 2x for five 90 minute sessions
Study NCT02951611 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Acupuncture stimulation
Description: Transcutaneous electrical acupoint stimulation on SI3, SJ6, PC6 and LI4